Jeffrey F Scherrer1,2, Joanne Salas1,2, Patrick Lustman3,4, Peter Tuerk5, Sarah Gebauer1,2, Sonya B Norman6, F David Schneider7, Kathleen M Chard8,9, Carissa van den Berk-Clark1, Beth E Cohen10,11, Paula P Schnurr12. 1. Department of Family and Community Medicine, Saint Louis University School of Medicine, USA. 2. Harry S. Truman Veterans Administration Medical Center, Columbia, USA. 3. Department of Psychiatry, Washington University School of Medicine, St. Louis, USA. 4. The Bell Street Clinic Opioid Addiction Treatment Programs, VA St. Louis Healthcare System, USA. 5. Sheila C. Johnson Center for Clinical Services, Department of Human Services, University of Virginia, Charlottesville, USA. 6. National Center for PTSD and Department of Psychiatry, University of California San Diego, USA. 7. Department of Family and Community Medicine, University of Texas Southwestern Medical Center, Dallas, USA. 8. Trauma Recovery Center Cincinnati VAMC, USA. 9. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, USA. 10. Department of Medicine, University of California San Francisco School of Medicine, USA. 11. San Francisco VAMC, USA. 12. National Center for PTSD and Department of Psychiatry, Geisel School of Medicine at Dartmouth, USA.
Abstract
AIM: Prescription opioid analgesic use (OAU) is associated with increased risk of cardiovascular disease (CVD). OAU is more common in patients with than without posttraumatic stress disorder (PTSD), and PTSD is associated with higher CVD risk. We determined whether PTSD and OAU have an additive or multiplicative association with incident CVD. METHODS AND RESULTS: Veterans Health Affairs patient medical record data from 2008 to 2015 was used to identify 2861 patients 30-70 years of age, free of cancer, CVD and OAU for 12 months before index date. We defined a four-level exposure variable: 1) no PTSD/no OAU, 2) OAU alone, 3) PTSD alone and 4) PTSD+OAU. Cox proportional hazard models estimated the association between the exposure variable and incident CVD. The mean age was 49.0 (±11.0), 85.7% were male and 58.3% were White, 34.4% had no PTSD/no OAU, 32.9% had PTSD alone, 10.6% had OAU alone, and 22.1% had PTSD+OAU. Compared with patients with no PTSD/no OAU, those with PTSD alone were not at increased risk of incident CVD (hazard ratio = 0.82; 95% confidence interval (CI): 0.63-1.17); however, OAU alone and PTSD+OAU were both significantly associated with incident CVD (hazard ratio = 1.99; 95% CI:1.36-2.92 and hazard ratio = 2.20; 95% CI: 1.61-3.02). There was no significant additive or multiplicative PTSD and OAU association with incident CVD. CONCLUSION: OAU is associated with nearly a two-fold increased risk of CVD in patients with and without PTSD. Despite no additive or multiplicative interaction effects, the high prevalence of OAU in PTSD may represent a novel contributor to the elevated CVD burden among patients with PTSD.
AIM: Prescription opioid analgesic use (OAU) is associated with increased risk of cardiovascular disease (CVD). OAU is more common in patients with than without posttraumatic stress disorder (PTSD), and PTSD is associated with higher CVD risk. We determined whether PTSD and OAU have an additive or multiplicative association with incident CVD. METHODS AND RESULTS: Veterans Health Affairs patient medical record data from 2008 to 2015 was used to identify 2861 patients 30-70 years of age, free of cancer, CVD and OAU for 12 months before index date. We defined a four-level exposure variable: 1) no PTSD/no OAU, 2) OAU alone, 3) PTSD alone and 4) PTSD+OAU. Cox proportional hazard models estimated the association between the exposure variable and incident CVD. The mean age was 49.0 (±11.0), 85.7% were male and 58.3% were White, 34.4% had no PTSD/no OAU, 32.9% had PTSD alone, 10.6% had OAU alone, and 22.1% had PTSD+OAU. Compared with patients with no PTSD/no OAU, those with PTSD alone were not at increased risk of incident CVD (hazard ratio = 0.82; 95% confidence interval (CI): 0.63-1.17); however, OAU alone and PTSD+OAU were both significantly associated with incident CVD (hazard ratio = 1.99; 95% CI:1.36-2.92 and hazard ratio = 2.20; 95% CI: 1.61-3.02). There was no significant additive or multiplicative PTSD and OAU association with incident CVD. CONCLUSION:OAU is associated with nearly a two-fold increased risk of CVD in patients with and without PTSD. Despite no additive or multiplicative interaction effects, the high prevalence of OAU in PTSD may represent a novel contributor to the elevated CVD burden among patients with PTSD.
Entities:
Keywords:
PTSD; cardiovascular disease; cohort; epidemiology; medical records; opioids
Authors: Wendy J Carman; Shuhua Su; Suzanne F Cook; John I Wurzelmann; Andrew McAfee Journal: Pharmacoepidemiol Drug Saf Date: 2011-05-12 Impact factor: 2.890
Authors: Jeffrey F Scherrer; Joanne Salas; Laurel A Copeland; Eileen M Stock; F David Schneider; Mark Sullivan; Kathleen K Bucholz; Thomas Burroughs; Patrick J Lustman Journal: J Pain Date: 2016-02-13 Impact factor: 5.820
Authors: Markus C Elze; John Gregson; Usman Baber; Elizabeth Williamson; Samantha Sartori; Roxana Mehran; Melissa Nichols; Gregg W Stone; Stuart J Pocock Journal: J Am Coll Cardiol Date: 2017-01-24 Impact factor: 24.094
Authors: Gad Abraham; Aki S Havulinna; Oneil G Bhalala; Sean G Byars; Alysha M De Livera; Laxman Yetukuri; Emmi Tikkanen; Markus Perola; Heribert Schunkert; Eric J Sijbrands; Aarno Palotie; Nilesh J Samani; Veikko Salomaa; Samuli Ripatti; Michael Inouye Journal: Eur Heart J Date: 2016-09-21 Impact factor: 29.983
Authors: Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.495